Austar Lifesciences Limited

SEHK:6118 Stock Report

Market Cap: HK$420.3m

Austar Lifesciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Mars Ho

Chief executive officer

CN¥895.0k

Total compensation

CEO salary percentage98.3%
CEO tenure10.3yrs
CEO ownership67.0%
Management average tenure9.8yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Apr 18
Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Mar 28
Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Feb 12
Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

Dec 22
Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

Sep 28
We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Mar 31
Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sep 19
Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Apr 06
Is Austar Lifesciences (HKG:6118) A Risky Investment?

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Oct 24
Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

Sep 27
With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

May 31
If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Mar 31
Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Mar 01
Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 01
Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Jan 11
Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Dec 21
Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Dec 07
Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Nov 23
Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

CEO Compensation Analysis

How has Mars Ho's remuneration changed compared to Austar Lifesciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-CN¥33m

Jun 30 2023n/an/a

CN¥2m

Mar 31 2023n/an/a

CN¥45m

Dec 31 2022CN¥895kCN¥880k

CN¥87m

Sep 30 2022n/an/a

CN¥96m

Jun 30 2022n/an/a

CN¥105m

Mar 31 2022n/an/a

CN¥191m

Dec 31 2021CN¥865kCN¥850k

CN¥277m

Sep 30 2021n/an/a

CN¥258m

Jun 30 2021n/an/a

CN¥238m

Mar 31 2021n/an/a

CN¥136m

Dec 31 2020CN¥927kCN¥911k

CN¥33m

Sep 30 2020n/an/a

CN¥25m

Jun 30 2020n/an/a

CN¥17m

Mar 31 2020n/an/a

CN¥12m

Dec 31 2019CN¥918kCN¥902k

CN¥8m

Sep 30 2019n/an/a

CN¥8m

Jun 30 2019n/an/a

CN¥8m

Mar 31 2019n/an/a

CN¥4m

Dec 31 2018CN¥880kCN¥865k

CN¥107k

Sep 30 2018n/an/a

-CN¥16m

Jun 30 2018n/an/a

-CN¥33m

Mar 31 2018n/an/a

-CN¥43m

Dec 31 2017CN¥1mCN¥1m

-CN¥54m

Compensation vs Market: Mars 's total compensation ($USD123.51K) is below average for companies of similar size in the Hong Kong market ($USD232.80K).

Compensation vs Earnings: Mars 's compensation has increased whilst the company is unprofitable.


CEO

Mars Ho (61 yo)

10.3yrs

Tenure

CN¥895,000

Compensation

Mr. Kwok Keung Ho, also known as Mars, is the Founder of Austar Lifesciences Limited and serves as its Chairman of the Board and Chief Executive Officer. Mr. Ho is responsible for overseeing the business,...


Leadership Team

NamePositionTenureCompensationOwnership
Kwok Keung Ho
Founderno dataCN¥895.00k67%
CN¥ 281.6m
Yuewu Chen
Executive Director9.8yrsCN¥1.47mno data
Ning Zhou
Executive Director9.8yrsCN¥1.15mno data
Kin Hung Ho
Executive Director9.8yrsCN¥2.40m7.27%
CN¥ 30.6m
Xiangdi Tang
Vice President of Corporate Development3.3yrsno datano data
Yuk Kiu Mak
Company Secretary1.5yrsno datano data

9.8yrs

Average Tenure

57yo

Average Age

Experienced Management: 6118's management team is seasoned and experienced (9.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kwok Keung Ho
Founder10.3yrsCN¥895.00k67%
CN¥ 281.6m
Yuewu Chen
Executive Director9.8yrsCN¥1.47mno data
Ning Zhou
Executive Director9.8yrsCN¥1.15mno data
Kin Hung Ho
Executive Director10.3yrsCN¥2.40m7.27%
CN¥ 30.6m
Lap Kei Cheung
Independent Non-Executive Director9.5yrsCN¥155.00kno data
Oi Kin Leung
Independent Non-Executive Director6.5yrsCN¥155.00kno data
Hoi Shan Chiu
Independent Non-Executive Director9.8yrsCN¥155.00kno data
Lingling Ji
Non-Executive Director9.8yrsCN¥648.00kno data

9.8yrs

Average Tenure

50.5yo

Average Age

Experienced Board: 6118's board of directors are considered experienced (9.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.